# A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

> **NCT07481981** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Insmed Incorporated** · enrollment: 344 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Treprostinil Palmitil Inhalation Powder
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07481981
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-17
- **Primary completion:** 2028-12-28
- **Final completion:** 2029-01-28
- **Target enrollment:** 344 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481981, "A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07481981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*